Dupixent (dupilumab) - Sanofi, Regeneron
Successful Long-Term Dupilumab Therapy for Refractory Prurigo Nodularis in a Child with XLA (ACAAI 2026) - Oct 28, 2026 - Abstract #M325; Pres time: Nov 13, 2026; 03:25 PM - 06:00 PM; Location: Phoenix Convention Center • North Halls 4–6 (Lower Level); Monitor 8; No abstract available 
Clinical • Immunology • Prurigo Nodularis
https://annualmeeting.acaai.org/2026/submit_abstract.cfm
 
Oct 28, 2026
 
Prev Next